VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
FULC
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
FULCFulcrum Therapeutics, Inc.
$3.72$201M
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
HomeStocksFULCBalance Sheet

Fulcrum Therapeutics, Inc. (FULC) Balance Sheet

9Y historyFree accessUpdated daily

Despite a nominal 31.35 current ratio, debt-to-equity of 0.02 ($5.3M debt vs. $310.7M equity), and zero goodwill or PPPE, the $639.3M accumulated deficit exceeds book equity twofold, and the reported $48.5M cash balance covers fewer than three quarters at recent burn rates, while equity has drawn down ~11% from $349.0M at 2025Q4.

Income StatementBalance SheetCash FlowRatios

FULC Balance Sheet

Annual statement

FULC Balance Sheet

Fulcrum Therapeutics, Inc. (FULC) balance sheet — 9-year assets, liabilities & shareholders' equity history

AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18Dec'17
Total Current Assets310.8M357.48M249.92M242.2M207.52M226M112.91M100.08M74.09M1.34M
Cash & Short-Term Investments306.55M352.31M241.02M236.22M202.92M218.16M112.91M96.71M72.8M407K
Cash Only116.41M197.53M58.21M25.56M35.1M35.41M57.05M96.71M72.8M407K
Short-Term Investments190.13M154.77M182.81M210.66M167.82M182.75M55.86M000
Accounts Receivable1.31M1.07M3.34M2.25M1.08M4.11M2.71M111K501K39K
Days Sales Outstanding--15.25292.6562.2178.28111.99---
Inventory00000-473K-2.78M2.98M559K734K
Days Inventory Outstanding-------528.92151.7374.7
Other Current Assets1.09M5.17M000074K284K238K248K
Total Non-Current Assets9K8.8M10.79M15.49M19.17M9M16.66M10.36M11.68M3M
Property, Plant & Equipment07.07M9.58M12.39M15.97M7.37M8.4M87.94M10.55M2.94M
Fixed Asset Turnover0.00x-8.35x0.23x0.40x2.60x1.05x---
Goodwill0000000000
Intangible Assets0000000000
Long-Term Investments00001.09M1.09M1.09M1.09M1.09M0
Other Non-Current Assets9K1.74M1.21M3.1M2.1M542K7.17M-78.68M38K60K
Total Assets310.81M366.28M260.72M257.69M226.69M235M129.58M110.44M85.77M4.34M
Asset Turnover0.00x-0.31x0.01x0.03x0.08x0.07x---
Asset Growth %169.62%40.49%1.17%13.68%-3.54%81.36%17.33%28.76%1876.29%-
Total Current Liabilities8.59M13.05M11.04M13.68M16.73M19.2M26.73M12.14M4.23M2.79M
Accounts Payable509K1.59M1.16M2.76M3.64M4.79M4.08M2.19M1.26M1.67M
Days Payables Outstanding1.31K418.046.714.0217.2925.0725.22388.65342.75854.05
Short-Term Debt00002.6M00000
Deferred Revenue (Current)0000934K4.71M14.91M3.99M2.8M0
Other Current Liabilities0258K463K396K5.34M4.71M4.79M3.68M781K20K
Current Ratio36.19x27.40x22.63x17.71x12.41x11.77x4.23x8.24x17.52x0.48x
Quick Ratio36.19x27.40x22.63x17.71x12.41x11.80x4.33x8.00x17.39x0.22x
Cash Conversion Cycle----------
Total Non-Current Liabilities197K4.24M6.64M8.83M11.02M4.26M7.67M11.15M5.54M233K
Long-Term Debt04.04M000000034.59M
Capital Lease Obligations2.76M06.44M8.63M10.82M00000
Deferred Tax Liabilities0000000000
Other Non-Current Liabilities197K197K197K197K04.26M4.7M5.13M5.54M-34.35M
Total Liabilities8.78M17.28M17.68M22.5M27.74M23.46M34.4M23.29M9.77M3.02M
Total Debt6.83M6.44M8.63M10.82M13.42M017K50K46K34.59M
Net Debt-109.58M-191.09M-49.58M-14.74M-21.68M-35.41M-57.03M-96.66M-72.75M34.18M
Debt / Equity0.02x0.02x0.04x0.05x0.07x-0.00x0.00x0.00x26.16x
Debt / EBITDA-0.09x---------
Net Debt / EBITDA1.46x---------
Interest Coverage----------
Total Equity302.03M349M243.03M235.19M198.94M211.54M95.18M87.15M76M1.32M
Equity Growth %186.66%43.6%3.33%18.22%-5.95%122.25%9.21%14.67%5648.87%-
Book Value per Share3.965.513.923.844.425.983.753.854.490.08
Total Shareholders' Equity302.03M349M243.03M235.19M198.94M211.54M95.18M87.15M76M1.32M
Common Stock76K67K54K62K52K41K28K23K16K1K
Retained Earnings-650.29M-594.28M-519.4M-509.67M-412.34M-302.47M-221.62M-150.8M-68.12M-35.54M
Treasury Stock0000000000
Accumulated OCI-759K174K130K-136K-797K-397K-2K-110.44M-1.96M-893K
Minority Interest0000000000

Key Metrics

Growth RegimeContracting
ProfitabilityNegative
Balance SheetMixed
Cash FlowBurning
Top Statement Risk

Sub-three-quarter cash runway

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q2)

Equity Reflated by Financing, Now Eroding

Total assets have fallen from $366.3M at 2025Q4 to $324.0M in 2026Q2 while equity declined from $349.0M to $310.7M, a roughly 11 percent drawdown in two quarters, per Fulcrum's quarterly balance sheet disclosures, driven almost entirely by accumulated losses rather than rising obligations.

The $150.6M equity increase between 2025Q3 and 2025Q4 appears consistent with an external capital raise that temporarily rebuilt the base after it had fallen to $198.4M, suggesting funding cadence, not operating performance, drove the most recent strengthening. Since that quarter, equity has given back $38.3M against a $45.0M deepening of accumulated deficit, a gap implying roughly $6.7M of non-loss equity additions, most plausibly stock-based compensation, partially offsetting the drain. Read alongside the prior finding that operating losses near $20M per quarter have not scaled down with R&D cuts, the trajectory suggests the equity cushion will continue to be consumed at a pace set by financing timing.

High Ratio Masks Short Runway

At 2026Q2 Fulcrum reported a 31.35 current ratio and $48.5M of cash against total liabilities of just $13.3M, a nominally fortress-style position, yet at the recent ~$16M quarterly operating cash burn disclosed in its filings the unencumbered cash appears to cover fewer than three quarters.

A current ratio above 31 against total liabilities of only $13.3M suggests minimal near-term obligation pressure, but the metric is flattered by an exceptionally small liability base rather than by abundant current assets, since cash of $48.5M appears to constitute most of the current account. Against quarterly outflows clustered near $16-19M in recent periods, the reported cash balance implies roughly three quarters of runway, so investors should read the ratio as a solvency signal rather than as a liquidity cushion. Cash has nonetheless printed $48.5M only two quarters after the apparent ~$150M equity raise, reinforcing that the cash line should not be evaluated in isolation from the remainder of the asset base.

Debt Runoff Removes Solvency Variable

Fulcrum's total debt has been steadily amortized to $5.3M as of 2026Q2 from $10.1M in 2024Q1, leaving a debt-to-equity ratio of 0.02, based on Fulcrum's reported figures, which suggests leverage servicing is negligible relative to the $310.7M equity base.

Debt has declined monotonically in each of the ten quarters shown, a pattern more consistent with scheduled amortization of a small facility than with covenant-driven repayment, although the data provided does not identify the underlying instrument. With total liabilities of just $13.3M and interest burden immaterial at this scale, refinancing risk appears negligible, which implies cash flow durability at Fulcrum is governed almost entirely by the R&D burn rate rather than by debt service. This removes one solvency variable but concentrates the funding question squarely on future equity issuance.

Asset-Light Base With Opaque Remainder

With goodwill at $0 and property, plant and equipment written down to $0 in 2026Q2 from $6.4M one quarter earlier, Fulcrum's balance sheet carries no acquired intangibles or fixed assets, according to its reported filings, leaving the composition of the remaining ~$275M of assets unexplained by disclosed line items.

The absence of goodwill and the run-off of net PPE from $11.4M in 2024Q1 to zero are consistent with the near-zero capex profile seen in cash flow disclosures, pointing to a fully outsourced, asset-light research model with no manufacturing infrastructure to underwrite. The disappearance of $6.4M of PPE within a single quarter, with no offsetting line visible in the data provided, warrants further investigation as it may reflect disposal, reclassification, or write-off. Because reported cash represents only about 15 percent of the $324.0M asset base, the quality and liquidity of the unitemized remainder appears central to any assessment of balance sheet真实 coverage.

Contributed Capital Fully Backstops Deficit

Fulcrum's accumulated deficit of $639.3M at 2026Q2 exceeds its entire $310.7M book equity by more than twofold, meaning the entire equity cushion traces to contributed capital, in the company's reported equity section, while quarterly losses near $20M continue to erode it.

Because accumulated deficit exceeds book equity by roughly 2x, the equity base is a function of historical share issuance rather than earned capital, leaving no retained-earnings buffer to absorb the current loss run-rate. Equity's $38.3M decline over the first half of 2026 against a $45.0M increase in accumulated deficit implies approximately $6.7M of equity additions from non-loss sources, which appears consistent with the recurring stock-based compensation previously identified and that dilutes holders without adding cash. The $55.4M equity improvement delivered by the 2024Q2 milestone has now been more than fully reversed, suggesting the windfall extended rather than reset the runway.

Unreconciled Cash Migration Clouds Liquidity

Cash fell $147.2M between 2025Q4 and 2026Q1 while total assets dropped only $19.5M and equity $15.7M, implying roughly $128M migrated into non-cash asset categories rather than being spent, per Fulcrum's balance sheets, a reclassification that makes the reported cash runway potentially misleading in either direction.

Total assets fell only $19.5M and equity $15.7M over the same period, so roughly $127.7M appears to have moved into asset categories not itemized in the data provided rather than being consumed by operations, an interpretation that warrants further investigation. If those balances are liquid marketable securities, runway may be materially longer than the $48.5M cash figure implies; if they are illiquid or restricted, headline liquidity could instead be overstated. This single unreconciled movement is the most consequential distortion in Fulcrum's reported balance sheet and should be resolved before sizing any going-concern buffer.

FULC — Frequently Asked Questions

Quick answers to the most common questions about buying FULC stock.

What are the total assets of Fulcrum Therapeutics, Inc. (FULC)?

As of 2025, Fulcrum Therapeutics, Inc. (FULC) had total assets of $366.3M including $357.5M in current assets.

How much debt does Fulcrum Therapeutics, Inc. (FULC) have?

Fulcrum Therapeutics, Inc. (FULC) carries total debt of $6.4M, offset by $352.3M in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.

What is the book value or shareholders' equity of Fulcrum Therapeutics, Inc.?

Fulcrum Therapeutics, Inc. (FULC) has total shareholders' equity (book value) of $349.0M ($5.51 book value per share). Book value represents the net worth of the company belonging to common stock holders.

What is Fulcrum Therapeutics, Inc.'s current ratio and liquidity?

Fulcrum Therapeutics, Inc. (FULC) reported a current ratio of 27.40x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.